Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies

The persistence and reactivity of CAR T cells were enhanced by adding co‐stimulatory domains, which is the basis of currently approved CAR‐T cell therapies. However, this comes at the expense of increasing toxicities from the strong cytokine release effect. This is the first report from anti‐CD19 CA...

Descripción completa

Detalles Bibliográficos
Autores principales: Shohdy, Kyrillus S., Pillai, Manon, Guest, Ryan, Rothwell, Dominic, Kirillova, Natalia, Chow, Shien, Gilham, David, Thistlethwaite, Fiona, Hawkins, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435680/
https://www.ncbi.nlm.nih.gov/pubmed/37601889
http://dx.doi.org/10.1002/jha2.731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435680/
https://www.ncbi.nlm.nih.gov/pubmed/37601889
http://dx.doi.org/10.1002/jha2.731

Ejemplares similares